BYSI Stock Catalyst: BeyondSpring's SEED Therapeutics Receives FDA Orphan Drug Designation for Neuroblastoma Treatment

BeyondSpring Inc. announced that its subsidiary, SEED Therapeutics, has received Orphan Drug Designation from the FDA for ST-01156. The designation is for the treatment of neuroblastoma, a rare form of cancer that primarily affects children.

The Orphan Drug Designation provides certain benefits, including tax credits for clinical trials, exemption from FDA user fees, and seven years of market exclusivity upon approval.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.